GPT and metabolic dysfunction-associated steatotic liver disease: In a study published in 2019 by our research group [106], after microarray analysis, the upregulation of RP11-128N14.5 lncRNA was validated in patients with severe NAFLD (NAS score ≥ 5 versus NAS score ≤ 4), with a diagnostic power of 0.71 (sensitivity = 73.7%, specificity = 70.4%) superior to AST (AUC = 0.66) and ALT (AUC = 0.37) (Figure 4).